NCT00913614View on ClinicalTrials.gov

Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Sleep Initiation and Maintenance Disorders
Interventions
DRUG

Eplivanserin (SR46349)

Oral administration

Trial Locations (1)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00913614 - Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia | Biotech Hunter | Biotech Hunter